• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Belite Bio, Inc - American Depositary Shares (NQ: BLTE )

    45.50 -0.32 (-0.70%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 33,815
    Open 45.88
    Bid (Size) 45.01 (10)
    Ask (Size) 48.51 (1)
    Prev. Close 45.82
    Today's Range 45.25 - 46.29
    52wk Range 12.53 - 50.15
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire

    Performance

    YTD
    +6.41%
    +6.41%
    1 Month
    -6.86%
    -6.86%
    3 Month
    +23.27%
    +23.27%
    6 Month
    +6.41%
    +6.41%
    1 Year
    +218.18%
    +218.18%

    More News

    Read More
    BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024
    Via InvestorPlace
    Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    Expert Ratings for Belite Bio
    Via Benzinga
    Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces $25 Million Registered Direct Offering
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio to Participate in the BTIG Ophthalmology Day
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
    From Virtual Investor Conferences
    Via GlobeNewswire
    Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
    From Belite Bio, Inc
    Via GlobeNewswire
    Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023
    From Virtual Investor Conferences
    Via GlobeNewswire
    Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
    From Belite Bio, Inc
    Via GlobeNewswire
    International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
    From Virtual Investor Conferences
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.